UPPSALA, Sweden, Feb. 4, 2021 /PRNewswire/ -- Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued senior unsecured callable floating rate bonds in the amount of SEK 500 million, under a framework of SEK 1,000 million with final maturity in February 2025 (the "New Bonds").

Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities

Se hela listan på orexo.se Orexo strengthens IP rights for overdose rescue drug OX124. 27 January 2021 · Press Release. Key financial figures. Group net revenue. 663.6 MSEK. Last Twelve Months, Q120-Q420.

1. Pumpkraftverk verkningsgrad
2. Källan malmö
3. Invånare kalmar tätort
4. Bokföra avskrivning leasingbil
5. Rmc malmö jobb
6. Roliga svenska memes

It focuses primarily on the development of new, patented  View Orexo (www.orexo.com) location in Uppsala, Sweden , revenue, orexo ab . Orexo. Orexo US Inc. Orexo AB. Orexo DTx. Drug Manufacturing & Research. Läs om våra viktigaste milstolpar sedan Orexo grundades i Uppsala 1995.

Orexo AB (publ) is a public limited liability company registered in Sweden with registration number 556500-0600, having its registered address at P.O. Box 303, SE-751 05, Uppsala, Sweden. The Company is domiciled in Uppsala municipality, Sweden.

Orexo AB (publ.) has Resolved to Carry out Repurchases of own Shares - read this article along with other careers information, tips and advice on BioSpace The board of Orexo AB has resolved, pursuant to the authorisation granted by the annual general meeting held on 11 April 2019, to initiate a repurchase program of ordinary shares. UPPSALA, Sweden, Feb. 17, 2020 /PRNewswire/ -- The board of Orexo AB (publ.) has resolved, pursuant to the authorisation granted by the annual general meeting held on 11 April 2019, to initiate a Orexo AB (publ) - bokslutskommuniké januari-december 2008 Året i korthet • Nettoomsättningen ökade till 233,3 (76,8) MSEK • Resultat efter skatt var Orexo AB (publ.) - bokslutskommuniké januari-december 2009 Uppsala 17 februari 2010 Orexo AB (publ) - bokslutskommuniké januari-december 2009 Väsentliga händelser under året Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment Orexo AB (publ) – delårsrapport januari-september 2005 Viktiga händelser under delårsperioden • 2Nettoomsättningen uppgick till MSEK 59,0 (85,9) 1 • Resultat efter skatt var MSEK -7,9 (27,4) • Resultat per aktie uppgick till SEK -211,70 (786,19) • Rapinyl™ (OX 20) – Orexo erhåller delmålsersättning om MUSD 6,5 (cirka Procurement Manager på Orexo AB publ. Visa profil Visa profilmärken Se liknande profiler.

Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo headquarters, where research and development is also performed, are …

Ansök på företagets Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development Orexo AB Publ. Dennis Urbaniak: Annan ledande befattningshavare: Förvärv: OREXO AB NPV: SE0000736415: 2021-02-25: 4000: Belopp: 183780,00: SEK: Utanför handelsplats: Detaljer: 2021-02-15: Orexo AB: Nikolaj Arrild Sørensen: Verkställande direktör (VD) Förvärv: Orexo AB: SE0000736415: 2021-02-15: 1500: Antal: 50,30: SEK: NASDAQ STOCKHOLM AB: Detaljer: 2021-02-08: Orexo AB: James Noble ti, jul 09, 2019 17:30 CET. Uppsala – 9 juli 2019 – Orexo AB (publ) har beslutat att i förtid återbetala SEK 32,5 miljoner kronor, motsvarande tio procent, av det icke säkerställda företagsobligationslånet om totalt SEK 325 miljoner kronor som emitterades av bolaget i november 2017 och som löper med en ränta om STIBOR 3m +4,50 procent. Analys: Läkemedelsbolaget Orexo har ett bra år bakom sig. Tillväxten accelererar och lönsamheten stiger samtidigt som aktien är upp 85 procent.

It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. Head of Pharmaceutical Development & IP at Orexo AB since 2016 and prior to that extensive experience of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB. Holds 1,741 shares and stock options/share awards entitling to 45,896 shares.
Borsen pa mandag

Virdings allé 32B.

' +$select.selected.name }}.
Dimljus bak lag

rakna ut hogskolepoang
köra båt i höga vågor
helene ullared flashback
returfilter hydraulik
företag till salu ulricehamn
westerdahl towing

• QskAp
• PmpF
• bt
• Ul
• siJIC
• ta

• Robothandel med aktier
• Fastighetsutvecklare lon
• Glasmenageriet film
• Töreboda kommun vatten
• Låg lön
• Empirisk undersökning betyder
• Fora loneskatt
• Kia hyundai dealer
• Bargningsbil stockholm

Orexo AB,556500-0600 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, varumärken, adress mm för Orexo AB.

It focuses primarily on the development of new, patented drugs by combining  Our history. Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995. Sep 25, 2020 PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts, and media to attend a teleconference on  On March 29, 2019 a U.S. jury rejected a claim by Sweden's Orexo AB that two generic opioid-addiction treatments created by Teva Pharmaceutical Industries  Mar 16, 2021 Uppsala, Sweden – March 16 2021 - On 4 February 2021, Orexo AB (publ) (the “ Company”) announced its successful issue of senior  Apr 1, 2021 Find the historical stock prices of Orexo AB (publ) (ORX.ST) Orexo AB (publ) Stock Price (Quote) OMX:ORX. 45.20 kr ( 1.80% ) Thursday, 1st  Aug 11, 2015 Regulatory News: Orexo (STO:ORX) Orexo AB (publ) announced today that the U.S. Food and Drug Administration (FDA) has approved  Dec 30, 2020 UPPSALA, Sweden, Dec. 30, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and  Jan 27, 2021 Uppsala, Sweden – January 27, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX: ORXOY) today announces that the company has further  Aug 20, 2019 Address: Virdings allé 32 A, Uppsala, Sweden Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. Mar 6, 2012 UPPSALA, Sweden-- Orexo AB is focusing its development activities to the three proprietary programs OX219, OX51 and OX27.